Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

(Shutterstock)
Key Takeaways
  • Pfizer discontinued development of the oral GLP-1 agonist danuglipron for obesity due to a single case of acute liver injury in a pharmacokinetic trial.

Investor outlook for Pfizer’s oral GLP-1 agonist danuglipron was already dampened, but now the obesity drug has officially been discontinued,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Business